Pharmaceuticals on the NGX
Every TNI analysis of pharmaceuticals companies, plus our sector scorecards.
Nigerian Pharma 9M 2026 Scorecard: May & Baker Wins on Quality, Fidson on Scale, MeCure Carries the Debt
A calmer naira and lower FX losses lifted every listed drugmaker in 2026. Only May & Baker turned that into clean, cash-backed, cheaply priced earnings.
9 November 2026 · Read analysis →Fidson 9M 2026: Profit Up 47%, but FX Did Most of the Heavy Lifting
Fidson's 9M profit jumped 47% to N11.74bn, but about 69% of the pre-tax gain came from vanished FX losses while receivables and debt ballooned.
9 November 2026 · Read analysis →MeCure 9M 2026: Operations Fire, but the Bank Takes Half
MeCure's EBIT jumped 34% to N17.5bn, but N8.8bn of finance costs, N55bn of net debt and a 28x P/E make it the sector's highest-risk growth story.
9 November 2026 · Read analysis →May & Baker 9M 2026: A 10-Point Margin Leap, Net Cash and a Single-Digit P/E
May & Baker's PAT rose 76% to N5.89bn on a 10ppt gross-margin jump. It holds net cash and trades near 9.7x trailing earnings, the best value in listed pharma.
9 November 2026 · Read analysis →